Edward Mathers has served on our board of directors since January 2017. Mr. Mathers has served as a general partner at New Enterprise Associates, Inc., or NEA, a private venture capital firm focusing on technology and healthcare investments, since November 2019.
He served as partner at NEA from August 2008 to October 2019. Prior to joining NEA, Mr. Mathers served as executive vice president, corporate development and venture at MedImmune, Inc., or MedImmune, a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures, Inc. Mr. Mathers currently serves on the board of directors of Rhythm Pharmaceuticals, Inc., Synlogic, Inc. (formerly known as Mirna Therapeutics, Inc.), Trevi Therapeutics, Inc. and Reneo Pharmaceuticals, Inc., all of which are publicly traded pharmaceutical companies, and he previously served on the board of directors of ObsEva SA from November 2015 to June 2023, Liquidia Technologies, Inc. from April 2009 to May 2019, Ra Pharmaceuticals, Inc. from February 2010 to April 2020, Akouos, Inc. from October 2017 to December 2022, and Mirum Pharmaceuticals, Inc. from November 2018 to September 2022, all of which are or were publicly traded pharmaceutical companies. Mr. Mathers received a B.S. in chemistry from North Carolina State University.
